BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-143@catalystbrief.girapphe.com
DTSTAMP:20261118T181546Z
LAST-MODIFIED:20261118T181546Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Readout: Novartis Pharmaceuticals — Remibrutinib [Feb 2027]
DESCRIPTION:Phase 3 primary completion: A Study to Evaluate Efficacy of Rem
 ibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic
  Spontaneous Urticaria Inadequately Controlled by Second Generation H1-ant
 ihistamines.\nSource: https://clinicaltrials.gov/study/NCT06868212\nhttps:
 //catalystbrief.girapphe.com/e/143?lang=en\nNot investment advice. Dates m
 ay change.
URL:https://catalystbrief.girapphe.com/e/143?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
